Evommune, Inc.
EVMN
$14.65
$0.584.12%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 233.33% | 233.33% | 85.71% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 233.33% | 233.33% | 85.71% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 233.33% | 233.33% | 85.71% | -- | -- |
| SG&A Expenses | 102.64% | 68.67% | 56.85% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.64% | 18.63% | 22.15% | -- | -- |
| Operating Income | -34.08% | -10.70% | -15.79% | -- | -- |
| Income Before Tax | -46.17% | 3.30% | -3.09% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.17% | 3.30% | -3.09% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.17% | 3.30% | -3.09% | -- | -- |
| EBIT | -34.08% | -10.70% | -15.79% | -- | -- |
| EBITDA | -34.61% | -10.93% | -15.94% | -- | -- |
| EPS Basic | 74.50% | 63.96% | 38.23% | -- | -- |
| Normalized Basic EPS | 73.91% | 63.27% | 36.85% | -- | -- |
| EPS Diluted | 74.50% | 63.96% | 38.23% | -- | -- |
| Normalized Diluted EPS | 73.91% | 63.27% | 36.85% | -- | -- |
| Average Basic Shares Outstanding | 1,387.85% | 827.10% | 304.39% | -- | -- |
| Average Diluted Shares Outstanding | 1,387.85% | 827.10% | 304.39% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |